A real-world experience with a thin-strut bioresorbable vascular scaffold system: a single-centre study

Area of Science:

• Interventional Cardiology
• Biomaterials Science
• Cardiovascular Research

Background:

• Metal-free, bioresorbable stents are needed to improve vasomotor function and reduce restenosis and thrombosis risks.
• Current options face challenges with restenosis and thrombosis, highlighting the need for advanced scaffold designs.

Purpose of the Study:

• To evaluate the safety and efficacy of the MeRes100 bioresorbable scaffold.
• To assess the scaffold's performance in complex de novo and in-stent restenotic coronary lesions.

Main Methods:

• Retrospective single-centre study of 86 patients with coronary artery disease.
• Implantation of next-generation MeRes100 sirolimus-eluting bioresorbable vascular scaffold.
• Follow-up up to 12 months post-procedure.

Main Results:

• Successful scaffold delivery and expansion in 98.84% of cases.
• Low in-hospital mortality rate of 1.16% (cardiac death).
• No major adverse cardiac events, scaffold thrombosis, myocardial infarction, or ischemia-driven target lesion revascularization reported during follow-up.

Conclusions:

• The MeRes100 sirolimus-eluting scaffold is a safe, reliable, and clinically acceptable option for treating coronary artery lesions.
• Preliminary data support its use in both de novo and in-stent restenotic lesions.
• Further long-term studies with larger patient cohorts are recommended.